Full Text View
Tabular View
No Study Results Posted
Related Studies
LBH589 and Gemcitabine in the Treatment of Solid Tumors
This study has been suspended.
( Suspended pending an amendment to the protocol for IV administration of LBH589 )
Study NCT00550199   Information provided by Sarah Cannon Research Institute
First Received: October 26, 2007   Last Updated: July 8, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Solid Tumors
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
LBH589, Gemcitabine
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Sarah Cannon Research Institute
SCRI Oncology Research Consortium
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services